Back to BAYRYView Full Landscape
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
6 competitors in Chronic Kidney Disease
DHCNLlorundrostat
DVAXHEPLISAV-B
Phase 3JNJepoetin alfa
Phase 2SNYSevelamer hydrochloride
Phase 2HSCSWSodium Bicarbonate
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA2/16/2022
Kerendia
Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. For study results with respect to renal and cardiovascular events, see section 5.1. Kerendia is indicated for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in adults.
View on EMADrug Science
Mechanism of action & safety profile
Developer
Related Pipeline
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts